Skip to main content
. 2021 Nov 2;14(11):e244069. doi: 10.1136/bcr-2021-244069

Table 2.

Frequency of presenting symptoms, signs, and investigations of ILBCL from varying cohorts

Cohort and date Murase et al5 Shimada et al3 4 Matsue et al2 Ferreri et al16 Ferreri et al6
Year 2007 2008–09 2019 2004 2007
Population no 96 106 42 38 50
Median age 67 67 73 70 68
Male (%) 52 56 52.4 45 46
Symptoms (%)
Constitutional (Fever, night sweats, weight loss, fatigue) 76 84 98 55 22–42
Neurological (dementia, cerebrovascular events, peripheral neuropathy) 27 25 45 34 42
Respiratory (dyspnoea, hypoxaemia / hypoxia, pulmonary involvement) 34 33 80 (hypoxia only) 3 18
Signs (%)
Cutaneous (nodules, plaques, macules, telangiectasia, oedema, pain) 15 17 14 39 38
Spleen 67 65 81 26 26
Liver 55 48 26 26
Lymph node involvement 11 11 8
Investigations (%)
Bone marrow (haemophagocytosis, atypical lymphoid cells, histiocytosis) 75 59 60 32 30
Haemoglobin <110–120 g/L 66 68 95 63 (<120) 66
White cells count <4.0×109/L 27 27 24 22
Platelets <100–150×109/L 58 58 69 29 (<150) 32
Albumin <30–36 g/L 47 61 86 18 (<36)
Elevated Lactate Dehydrogenase (greater than upper limit of normal) 93 98 100 (median—934 units/L) 86 85
Elevated Soluble Interluekin-2 Receptor (>5000 U/mL) 56 66 69 (median—6886 units/mL)
Blood film: atypical lymphoid cells 24 34 14 5 4

ILBCL, intravascular large B-cell lymphoma.